Pfizer Rare Disease Plans Back On Track With Resubmission of Tafamidis
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer gained the therapy to treat a rare genetic neurologic disorder in its 2010 acquisition of folded protein company FoldRx.
You may also be interested in...
Pfizer, CFF Focus On Possible Combination Approach To Treating CF’s Underlying Cause
Building upon CFTR-focused drugs pioneered by Vertex’s Kalydeco, Pfizer will receive up to $58 million in R&D funding from the Cystic Fibrosis Foundation to bring new CF candidates into the clinic.
Pfizer Vyndaqel Advisory Committee Pits Orphan Flexibility Vs. Data Shortcomings
FDA finds much to question in a single pivotal trial of Pfizer’s orphan drug Vyndaqel (tafamidis meglumine) for familial amyloid polyneuropathy, but the ultra-orphan nature of the disease may outweigh those concerns.
Will Advisory Committee Review Vindicate Pfizer’s Vyndaqel?
Pfizer’s orphan drug tafamidis will be reviewed by FDA’s Peripheral and Central Nervous System Drugs Advisory Committee in May. The scheduling of a panel during a priority review is some indication FDA has concern, but the panels of outside experts are generally receptive to rare disease treatments.